EVOK News and Press, Evoke Pharma Inc. From 05/23/22

Gainers: GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Allarity Therapeutics (ALLR) +14%. Tonix Pharmaceuticals (TNXP) +13%. TRxADE HEALTH (MEDS) +13%. Losers: Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%. NanoViricides...

Evoke Pharma (NASDAQ:EVOK) announced on Monday that a real-world data analyses showed a lower risk of tardive dyskinesia among gastroparesis patients treated with metoclopramide compared to previous reports. Evoke's flagship product, Gimoti, is an FDA-approved nasal formulation of m...

Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide Supports Safety Profile of Only Approved Molecule in US to Treat Symptoms of Acute and Recurrent Dia...

SOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science ...

Penny stocks are shares of companies trading below $5. But for some traders, their focus is on the cheapest stocks in the market. These are the ones trading for actual pennies per share. Yes, stocks under $1 are a target for day traders and investors alike. In the short term, volatility is ...

SOLANA BEACH, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, today announced that its management team w...

Evoke Pharma, Inc. EVOK Q1 2022 Earnings Conference Call May 10, 2022, 4:30 PM ET Company Participants David Gonyer – Chief Executive Officer Chris Quesenberry – Chief Commercial Officer, EVERSANA Matthew D'Onofrio – Chief Business Officer Daniel Kontoh-Boateng – I...

Evoke Pharma press release (NASDAQ:EVOK): Q1 GAAP EPS of -$0.07 misses by $0.03. Revenue of $0.42M (+366.7% Y/Y) misses by $0.12M. Existing cash and cash equivalents of $7.7M, as well as future cash flows from net product sales of GIMOTI, will be sufficient to fund our operations into the sec...

SOLANA BEACH, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2022, and recent corpo...

Most people think of penny stocks as shares of companies trading for pennies. The standard definition considers these as stocks under $5, but you can’t argue with popular opinion. The exciting part about penny stocks under $1 is the volatility and gain potential they hold. Ca...